Table 3.
Platelet counts pre– and post–SARS-CoV-2 vaccination in patients with preexisting ITP
| Median [IQR], or n (%) | N | |
|---|---|---|
| Dose 1 | ||
| Platelet count prevaccination (×109/L) | 101 [60-199] | 109 |
| Timing of prevaccination platelet count(d)) | 14 [4.5-34] | 93 |
| Platelet count at first post-vaccine assessment (×109/L)* | 100 [50.5-195] | 109 |
| Timing of first postvaccination platelet count (d) | 6 [4-9] | 99 |
| Timing of platelet nadir† (d) | 6 [4.8-9.3] | 30 |
| Platelet count nadir† (×109/L) | 46.8 [27.8-93.3] | 34 |
| Platelet count 11-29 ×109/L | 7 (20.6) | 34 |
| Platelet count ≤10 ×109/L | 3 (8.8) | 34 |
| Dose 2 | ||
| Platelet count prevaccination (×109/L) | 101 [59.8-186] | 70 |
| Timing of prevaccination platelet count (d) | 11.5 [3-30] | 64 |
| Platelet count at first postvaccine assessment (×109/L) | 105.5 [52.8-202] | 70 |
| Timing of first postvaccination platelet count (d) | 5 [3-7.5] | 69 |
| Timing of platelet nadir† (d) | 5 [2.5-8.5] | 21 |
| Platelet count nadir† (×109/L) | 34 [10.5-116] | 21 |
| Platelet count 11-30 ×109/L | 5 (22.7) | 21 |
| Platelet count ≤10 ×109/L | 5 (23.8) | 21 |
*
Does not include 2 patients with “normal” platelet count.
†
Includes only patients with decrease >20% in platelet count.